BIOSYNTH LIMITED

05771788
Active United Kingdom

Manufacture of other chemical products n.e.c.

122 employees website.com
Life sciences and medical technology Manufacture of other chemical products n.e.c.Wholesale of pharmaceutical goods +2
B

BIOSYNTH LIMITED

05771788

Manufacture of other chemical products n.e.c.

Founded 6 Apr 2006 Active United Kingdom 122 employees website.com
Life sciences and medical technology Manufacture of other chemical products n.e.c.Wholesale of pharmaceutical goodsWholesale of chemical productsOther research and experimental development on natural sciences and engineering

Previous Company Names

CARBOSYNTH LIMITED 6 Apr 2006 — 7 Sept 2022
Accounts Submitted 10 Jul 2025 Next due 30 Sept 2026 2 months remaining
Confirmation Submitted 27 Apr 2026 Next due 2 May 2027 10 months remaining
Net assets £-7M £8M 2024 year on year
Total assets £17M £254K 2024 year on year
Total Liabilities £23M £8M 2024 year on year
Charges 10
1 outstanding 9 satisfied

Contact & Details

Contact

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for BIOSYNTH LIMITED (05771788), an active life sciences and medical technology company based in United Kingdom. Incorporated 6 Apr 2006. Manufacture of other chemical products n.e.c.. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 2 months remaining

Balance Sheet & P&L (2014–2024)

Cash in Bank

£675.67k

Increased by £261.94k (+63%)

Net Assets

-£6.54M

Decreased by £8.21M (-492%)

Total Liabilities

£23.15M

Increased by £8.46M (+58%)

Turnover

£9.90M

Decreased by £6.40M (-39%)

Employees

122

Decreased by 2 (-2%)

Debt Ratio

139%

Increased by 49 (+54%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

1 Allotment 500 Shares £309.81m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
20 Dec 2013500£309.81m£620k

Officers

Officers

2 active 1 resigned
Status
Patrick MeiliDirectorSwissSwitzerland571 Feb 2020Active
Rogers, Bruce Rajan, DrDirectorBritishEngland5226 Jun 2020Active

Shareholders

Shareholders (2)

Biosynth Holdings Ltd
100.0%
2,000
Healtang Biotech Co,. Ltd
0.0%
0

Persons with Significant Control

Persons with Significant Control (1)

1 Active
Active
Notified 6 Apr 2016
Nature of Control
  • Ownership Of Shares 75 To 100 Percent

Group Structure

Group Structure

BIOSYNTH LIMITED Current Company

Charges

Charges

1 outstanding 9 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
27 Apr 2026Confirmation StatementConfirmation statement made on 18 Apr 2026 with updates
23 Jan 2026OfficersTermination of Wubao Wang as director on 22 Jan 2026
16 Jan 2026OfficersTermination of Simon George Nutbrown as director on 16 Jan 2026
18 Nov 2025OfficersAppointment of Mr Matthew Tower Gunnison as director on 10 Nov 2025
18 Nov 2025OfficersTermination of Patrick Meili as director on 10 Nov 2025
27 Apr 2026 Confirmation Statement

Confirmation statement made on 18 Apr 2026 with updates

23 Jan 2026 Officers

Termination of Wubao Wang as director on 22 Jan 2026

16 Jan 2026 Officers

Termination of Simon George Nutbrown as director on 16 Jan 2026

18 Nov 2025 Officers

Appointment of Mr Matthew Tower Gunnison as director on 10 Nov 2025

18 Nov 2025 Officers

Termination of Patrick Meili as director on 10 Nov 2025

Recent Activity

Latest Activity

Confirmation statement made on 18 Apr 2026 with updates

2 months ago on 27 Apr 2026

Termination of Wubao Wang as director on 22 Jan 2026

5 months ago on 23 Jan 2026

Termination of Simon George Nutbrown as director on 16 Jan 2026

5 months ago on 16 Jan 2026

Appointment of Mr Matthew Tower Gunnison as director on 10 Nov 2025

7 months ago on 18 Nov 2025

Termination of Patrick Meili as director on 10 Nov 2025

7 months ago on 18 Nov 2025